Health Insurance - Epinephrine Injectors - Limits on Cost Sharing (Epinephrine Cost Reduction Act of 2024)
Impact
If enacted, HB 939 will significantly affect health insurance policies and practices within the state. The law will ensure that individuals who need epinephrine injectors—crucial for treating anaphylaxis—will face a reduced financial burden when accessing these medications. This is particularly important given the rising costs of healthcare and the need to make life-saving medical treatments more accessible. In effect, the bill aims to ensure that cost does not prevent individuals from obtaining the necessary care during emergencies.
Summary
House Bill 939, formally known as the Epinephrine Cost Reduction Act of 2024, aims to limit the cost-sharing obligations for individuals who require prescription epinephrine injectors. This legislation mandates that specific health insurance providers, including insurers, nonprofit health service plans, and health maintenance organizations, cannot charge more than $60 in total copayments, coinsurance, and deductibles for a medically necessary twin-pack of epinephrine injectors. The bill is targeted towards enhancing access to this critical medical device, which is essential for individuals at risk of severe allergic reactions.
Contention
While the motivations behind HB 939 are largely seen as positive, addressing the needs of individuals experiencing life-threatening allergies, there may still be dissent regarding the implications for insurance providers. Some may argue that these limits on cost sharing could impose additional financial pressures on insurers, potentially leading to higher premiums for other policyholders. There may also be concerns regarding the specifics of implementation—the feasibility of monitoring compliance and how insurers will adapt to these requirements while remaining financially viable. Nevertheless, the legislation seeks to strike a balance between affordability for consumers and the operational capabilities of insurance entities.
In school health services, further providing for definitions, for possession and use of asthma inhalers and epinephrine auto-injectors, for school access to emergency epinephrine and for administration of epinephrine auto-injectors by school bus drivers and school crossing guards.
In epinephrine auto-injector entities, further providing for definitions and for epinephrine auto-injectors for authorized entities; and making an editorial change.
In epinephrine auto-injector entities, further providing for definitions and for epinephrine auto-injectors for authorized entities; and making an editorial change.
In school health services, further providing for definitions, for possession and use of asthma inhalers and epinephrine auto-injectors, for school access to emergency epinephrine and for administration of epinephrine auto-injectors by school bus drivers and school crossing guards.
In epinephrine auto-injector entities, further providing for scope of chapter, for definitions and for epinephrine auto-injectors for authorized entities; and making an editorial change.